What was the Diabetes Prevention Trial--Type 1?
The Diabetes Prevention Trial--Type 1 (DPT-1) consisted of two clinical trials that sought to delay or prevent type 1 diabetes, also known as insulin-dependent diabetes. Nine medical centers and more than 350 clinics in the United States and Canada took part in the two trials of the DPT-1.
Who was eligible to participate in these trials? Individuals who were eligible for testing were: Ages 3 to 45 with a brother or sister, child, or parent with type 1 diabetes.
Diabetes has a genetic link; close relatives of people with the disease have an increased chance of developing it. All family members, including children, were eligible for a free test to determine their risk of getting diabetes.
Ages 3 to 20 with a cousin, uncle or aunt, nephew or niece, grandparent, or half-sibling with type 1 diabetes. Those who met these criteria could receive a free blood test to see whether they had islet cell antibodies (ICA), the antibodies that destroy the insulin-producing cells. To be eligible, a person's blood had to be positive for ICAs.
How did the DPT-1 trials try to prevent type 1 diabetes?
Animal research and small studies in people indicated that small, regular doses of insulin could prevent or delay type 1 diabetes in those at risk. One DPT-1 trial tested whether low-dose insulin injections could prevent or delay the development of type 1 diabetes in people at high risk for developing type 1 diabetes within 5 years. The other was an oral insulin trial that sought to prevent type 1 diabetes in people with a moderate risk for developing diabetes.
What were the findings of these trials?
Neither low-dose insulin injections in people at high risk for developing type 1 diabetes nor insulin capsules taken orally by people at moderate risk for type 1 diabetes were successful at preventing or delaying diabetes. The findings of the low-dose insulin injection trial were published in the May 30, 2002 issue of the New England Journal of Medicine. The oral insulin trial results were announced on June 10, 2003, at the American Diabetes Association annual meetings.
Where did the DPT-1 trials take place?
More than 350 screening centers in the United States and Canada were linked with the following DPT-1 clinical centers.
Children's Hospital of Los Angeles
Box 61/ 4650 Sunset Boulevard
Los Angeles, CA 90027
Fax: (323) 953-1349
University of Southern California
Los Angeles County Medical Center
Endocrine & Diabetes Service, Rm. 19629B
Los Angeles, CA 90033
Phone: (323) 226-7626
Fax: (323) 226-5709
S-302 Medical Center
Stanford, CA 94305-5119
Phone: (650) 725-0497
Fax: (650) 725-8375
Barbara Davis Center for Childhood Diabetes
Box B140/ 4200 East 9th Avenue
University of Colorado
Denver, CO 80262
Fax: (303) 315-4124
University of Florida
Gainesville, FL 32610-0296
Phone: 1-800-749-7424, ext. 2-7836
Phone: (352) 392-7836
Fax: (352) 392-3053
University of Miami
P. O. Box 016960 (D-110)
Miami, FL 33101
Phone: (305) 243-DPT-1 (305-243-3781)
Fax: (305) 243-3313
Joslin Diabetes Center/Children's Hospital /Beth Israel Hospital
1 Joslin Place
Boston, MA 02215
Phone: 1-800-2-HALT-DM (1-800-242-5836)
Fax: (617) 732-2432
University of Minnesota
424 Harvard Street SE, Box 101
Masonic Bldg. Room 203
Minneapolis, MN 55455
Phone: 1-800-688-5252, ext. 58944
Fax: (612) 626-3133
Virginia Mason Research Center
1201 9th Avenue
Seattle, WA 98101
Phone: (206) 515-5233
Fax: (206) 515-5239
Who sponsored the trials?
National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, American Diabetes Association, Juvenile Diabetes Research Foundation International, and National Center for Research Resources.
Additional promotional support and supplies provided by: Eli Lilly and Company, Becton-Dickinson & Co., Abbott Laboratories, Medisense Products, Bayer Corporation, Bristol-Myer Squibb Company, Lifescan Inc., MiniMed Inc., Roche Diagnostics.
Last Updated: 7-17-03